Skip to main content
. 2016 Dec 8;20(1):40–49. doi: 10.1093/ijnp/pyw093

Figure 5.

Figure 5.

Change from baseline to week 28 in patient-rated (a) Subjective Well-Being Under Neuroleptics–short version (SWN-S) total and subscale scores and (b) Tolerability and Quality of Life (TooL) total score. Full analysis set. AOM 400, aripiprazole once-monthly 400 mg; FAS, full analysis set; LS, least squares. *n=83 for the PP treatment group.